Table 6 Study design and results for five studies investigating COVID-19 mortality in patients with cancer infected with SARS-Cov-2
Data | CCC19 (ref. 9) | UK Coronavirus Cancer Monitoring Project13 | Gustave Roussy cohort | TERAVOLT10 | Curie cohort34 |
|---|---|---|---|---|---|
Patients with cancer (n) | 928 | 800 | 178 | 200 | 76 |
Cancer population | All cancers | All cancers | All cancers | Thoracic cancer | Breast cancer |
Multicentric | Yes | Yes | No | Yes | No |
Median follow-up | 21 d | Not specified | 23 d | 15 d | Not specified |
Primary endpoint | All-cause mortality within 30 d of diagnosis of COVID-19 | All-cause mortality | All-cause mortality and clinical worsening-free survival | All-cause mortality | Death or ICU admission |
Inclusion of biological findings | No | No | Yes | No | Yes |
Inclusion of CT findings | No | No | Yes | No | Yes |
Inclusion of type of cancer systemic treatment used (delay before COVID-19) | Yes (1 month) | Yes (1 month) | Yes (3 months) | Yes (not specified) | Yes (1 month) |
Inclusion of COVID-19 systemic treatment used | Yes | No | Yes | No | Yes |
Inclusion of impact on cancer treatment strategy after COVID-19 diagnosis | No | No | Yes | No | No |
Prognostic factors of death studied in univariable analysis | Increased age (per 10 years), male sex, smoking status (former smoker versus never smoked), number of comorbidities (two versus none), type of malignancy (multiple cancers versus only solid tumor), active cancer (progressing versus remission), ECOG score ≥2 and azithromycin/hydroxychloroquine treatment | Age, male sex, hypertension, cardiovascular disease, COVID-19 severity score, ICU admission and shortness of breath | Age ≥70 years, smoking status (current and former), ECOG score ≥2 at last follow-up, onco-hematological status (metastatic disease), use of cytotoxic chemotherapy in past 3 months and levels of CRP, procalcitonin, lymphopenia, monocytopenia, ferritin, LDH, albumin and troponin | Age >65 years, smoking status (current versus former smoker), treatment with chemotherapy, presence of any comorbidities and dyspnea | Age (>70 years) and hypertensiona |
Prognostic factors of death studied in multivariate analysis | Increased age (OR = 1.84; 95% CI = 1.53–2.21), male sex (OR = 1.63; 95% CI = 1.07–2.48), smoking status (OR = 1.60; 95% CI = 1.03–2.47), number of comorbidities (2 versus 0) (OR = 4.50; 95% = 1.33–15.28), ECOG score ≥2 (OR = 3.89; 95% CI = 2.11–7.18), active cancer (progressing versus remission) (OR = 5.20; 95% CI = 2.77–9.77) and azithromycin/hydroxychloroquine treatment (OR = 2.93; 95% CI = 1.79–4.79) | Noneb | ECOG score at last follow-up ≥2 (HR = 5.83; 95% CI = 2.60–13.1), CRP levels (HR = 2.80; 95% CI = 1.01–7.78) and D-dimer levels (HR = 2.63; 95% CI = 1.15–6.01) | Smoking history (OR = 3.18; 95% CI = 1.11–9.06) | Not done |
